Endoplasmic reticulum and lysosomal Ca2+ stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts

Cell Calcium

Volumn 59, Issue 1, 2016, Pages 12-20

  Kilpatrick, Bethan S ^a   Magalhaes, Joana ^b   Beavan, Michelle S ^b   McNeill, Alisdair ^b   Gegg, Matthew E ^b   Cleeter, Michael W J ^b   Bloor Young, Duncan ^c   Churchill, Grant C ^c   Duchen, Michael R ^a   Schapira, Anthony H ^b   Patel, Sandip ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Ca2+; Endoplasmic reticulum; Gaucher disease; Lysosomes; Parkinson disease

Indexed keywords

CALCIUM ION; GLUCOSYLCERAMIDASE; CALCIUM; GBA1 PROTEIN, ZEBRAFISH; ZEBRAFISH PROTEIN;

ADULT; AGED; ARTICLE; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CALCIUM TRANSPORT; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME INHIBITION; GAUCHER DISEASE; GBA1 GENE; GENE MUTATION; HUMAN; HUMAN CELL; LYSOSOME; ORGANELLE SHAPE; PARKINSON DISEASE; PRIORITY JOURNAL; CELL CULTURE; FIBROBLAST; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CALCIUM; CELL LINE, TUMOR; CELLS, CULTURED; ENDOPLASMIC RETICULUM; FIBROBLASTS; GLUCOSYLCERAMIDASE; HUMANS; LYSOSOMES; PARKINSON DISEASE; ZEBRAFISH PROTEINS;

EID: 84958110808     PISSN: 01434160     EISSN: 15321991     Source Type: Journal    
DOI: 10.1016/j.ceca.2015.11.002     Document Type: Article

References (41)

1. Berridge M.J., Lipp P., Bootman M.D. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 2000, 1:11-21. 10.1038/35036035.
2. Clapham D.E. Calcium signaling. Cell 2007, 131:1047-1058. 10.1016/j.cell.2007.11.028.
3. Lee H.C. Cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate (NAADP) as messengers for calcium mobilization. J. Biol. Chem. 2012, 287:31633-31640. 10.1074/jbc.R112.349464.
4. 2+ signaling. Trends Cell Biol. 2010, 20:277-286. 10.1016/j.tcb.2010.02.003.
5. Patel S., Muallem S. Acidic Ca(2+) stores come to the fore. Cell Calcium 2011, 50:109-112. 10.1016/j.ceca.2011.03.009.
6. 2+ signals. J. Cell Sci. 2013, 126:60-66. 10.1242/jcs.118836.
7. Vitner E.B., Platt F.M., Futerman A.H. Common and uncommon pathogenic cascades in lysosomal storage diseases. J. Biol. Chem. 2010, 285:20423-20427. 10.1074/jbc.R110.134452.
8. Platt F.M. Sphingolipid lysosomal storage disorders. Nature 2014, 510:68-75. 10.1038/nature13476.
9. Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G., Barbosa E.R., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 2009, 361:1651-1661. 10.1056/NEJMoa0901281.
10. Dehay B., Martinez-Vicente M., Caldwell G.A., Caldwell K.A., Yue Z., Cookson M.R., et al. Lysosomal impairment in Parkinson's disease. Mov. Disord. 2013, 28:725-732. 10.1002/mds.25462.
11. Beavan M.S., Schapira A.H.V. Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann. Med. 2013, 45:511-521. 10.3109/07853890.2013.849003.
12. Osellame L.D., Rahim A.A., Hargreaves I.P., Gegg M.E., Richard-Londt A., Brandner S., et al. Mitochondria and quality control defects in a mouse model of Gaucher disease-links to Parkinson's disease. Cell Metab. 2013, 17:941-953. 10.1016/j.cmet.2013.04.014.
13. Schapira A.H.V., Olanow C.W., Greenamyre J.T., Bezard E. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 2014, 384:545-555. 10.1016/S0140-6736(14)61010-2.
14. Surmeier D.J., Guzman J.N., Sanchez-Padilla J. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease. Cell Calcium 2010, 47:175-182. 10.1016/j.ceca.2009.12.003.
15. Korkotian E., Schwarz A., Pelled D., Schwarzmann G., Segal M., Futerman A.H. Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J. Biol. Chem. 1999, 274:21673-21678.
16. Lloyd-Evans E., Morgan A.J., He X., Smith D.A., Elliot-Smith E., Sillence D.J., et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med. 2008, 14:1247-1255. 10.1038/nm.1876.
17. Shachar T., Lo Bianco C., Recchia A., Wiessner C., Raas-Rothschild A., Futerman A.H. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov. Disord. 2011, 26:1593-1604. 10.1002/mds.23774.
18. Guzman J.N., Sánchez-Padilla J., Chan C.S., Surmeier D.J. Robust pacemaking in substantia nigra dopaminergic neurons. J. Neurosci. 2009, 29:11011-11019. 10.1523/JNEUROSCI.2519-09.2009.
19. Chan C.S., Guzman J.N., Ilijic E., Mercer J.N., Rick C., Tkatch T., et al. "Rejuvenation" protects neurons in mouse models of Parkinson's disease. Nature 2007, 447:1081-1086. 10.1038/nature05865.
20. Guzman J.N., Sanchez-Padilla J., Wokosin D., Kondapalli J., Ilijic E., Schumacker P.T., et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010, 468:696-700. 10.1038/nature09536.
21. McNeill A., Magalhaes J., Shen C., Chau K.-Y., Hughes D., Mehta A., et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 2014, 137:1481-1495. 10.1093/brain/awu020.
22. Cleeter M.W.J., Chau K.-Y., Gluck C., Mehta A., a Hughes D., Duchen M., et al. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem. Int. 2013, 62:1-7. 10.1016/j.neuint.2012.10.010.
23. Rosen D., Bloor-Young D., Squires J., Parkesh R., Waters G., Vasudevan S.R., et al. Synthesis and use of cell-permeant cyclic ADP-ribose. Biochem. Biophys. Res. Commun. 2012, 418:353-358. 10.1016/j.bbrc.2012.01.025.
24. Hockey L.N., Kilpatrick B.S., Eden E.R., Lin-Moshier Y., Brailoiu G.C., Brailoiu E., et al. Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition. J. Cell Sci. 2015, 128:232-238. 10.1242/jcs.164152.
25. Kilpatrick B.S., Eden E.R., Hockey L.N., Futter C.E., Patel S. Methods for monitoring lysosomal morphology. Methods Cell Biol. 2015, 126:1-19. 10.1016/bs.mcb.2014.10.018.
26. Collier T.J., Kanaan N.M., Kordower J.H. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat. Rev. Neurosci. 2011, 12:359-366. 10.1038/nrn3039.
27. Sidransky E., Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol. 2012, 11:986-998. 10.1016/S1474-4422(12)70190-4.
28. 2+ microdomains. J. Cell Sci. 2014, 127:2934-2943. 10.1242/jcs.149047.
29. Schöndorf D.C., Aureli M., McAllister F.E., Hindley C.J., Mayer F., Schmid B., et al. iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat. Commun. 2014, 5:4028. 10.1038/ncomms5028.
30. 2+ increases enhance mutant glucocerebrosidase proteostasis. Nat. Chem. Biol. 2010, 6:424-432. 10.1038/nchembio.368.
31. Coen K., Flannagan R.S., Baron S., Carraro-Lacroix L.R., Wang D., Vermeire W., et al. Lysosomal calcium homeostasis defects, not proton pump defects, cause endo-lysosomal dysfunction in PSEN-deficient cells. J. Cell Biol. 2012, 198:23-35. 10.1083/jcb.201201076.
32. Lee J.-H., McBrayer M.K., Wolfe D.M., Haslett L.J., Kumar A., Sato Y., et al. Presenilin 1 maintains lysosomal Ca(2+) homeostasis via TRPML1 by regulating vATPase-mediated lysosome acidification. Cell Rep. 2015, 10.1016/j.celrep.2015.07.050.
33. Luzio J.P., Bright N.A., Pryor P.R. The role of calcium and other ions in sorting and delivery in the late endocytic pathway. Biochem. Soc. Trans. 2007, 35:1088-1091. 10.1042/BST0351088.
34. Dehay B., Ramirez A., Martinez-Vicente M., Perier C., Canron M.-H., Doudnikoff E., et al. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:9611-9616. 10.1073/pnas.1112368109.
35. Gómez-Suaga P., Luzón-Toro B., Churamani D., Zhang L., Bloor-Young D., Patel S., et al. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum. Mol. Genet. 2012, 21:511-525. 10.1093/hmg/ddr481.
36. Dodson M.W., Zhang T., Jiang C., Chen S., Guo M. Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum. Mol. Genet. 2012, 21:1350-1363. 10.1093/hmg/ddr573.
37. Schreij A.M.A., Chaineau M., Ruan W., Lin S., Barker P.A., Fon E.A., et al. LRRK2 localizes to endosomes and interacts with clathrin-light chains to limit Rac1 activation. EMBO Rep. 2015, 16:79-86. 10.15252/embr.201438714.
38. Mazzulli J.R., Xu Y.-H., Sun Y., Knight A.L., McLean P.J., Caldwell G.A., et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146:37-52. 10.1016/j.cell.2011.06.001.
39. Duran R., Mencacci N.E., Angeli A.V., Shoai M., Deas E., Houlden H., et al. The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Mov. Disord. 2013, 28:232-236. 10.1002/mds.25248.
40. Gegg M.E., Sweet L., Wang B.H., Shihabuddin L.S., Sardi S.P., Schapira A.H.V. No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov. Disord. 2015, 30:1085-1089. 10.1002/mds.26278.
41. Gegg M.E., Burke D., Heales S.J.R., Cooper J.M., Hardy J., Wood N.W., et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 2012, 72:455-463. 10.1002/ana.23614.